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Invasive fungal infections have been reported in 5% to
59% of organ transplant recipients (1-4). Infections due to
Cryptococcus neoformans, while less common than those due
to  Candida and mycelial fungi, are also an important
posttransplant complication. The incidence of invasive
candidiasis has declined in subsets of organ transplant
recipients (e.g., liver transplant patients) as a result of
fluconazole use and technologic advances in surgery (5).
However, the risk factors and pathogenesis of C. neoformans
infection in the transplant setting are poorly understood, and
fluconazole prophylaxis is generally not used in the late
posttransplant period when cryptococcal infections usually
occur. Thus, the incidence and impact of cryptococcal infection
in organ transplant recipients are unlikely to diminish in the
foreseeable future. Indeed, as incidence of C. neoformans
infection in HIV-infected patients has declined, organ
transplant recipients have become the group of immunocom-
promised patients at highest risk for cryptococcosis. The
overall death rate in transplant recipients with cryptococcal
infection has been 20% to 100% (6-9). While the predictors of
outcome in patients with C. neoformans have been well
documented in nontransplant settings (10-12), predictors in
transplant recipients are largely unknown. The unique
neurotropism and predilection of C. neoformans to cause central
nervous system (CNS) infections are well recognized; CNS
has been the most common site for cryptococcal infections.
However, 67% of our liver transplant recipients with
cryptococcosis who received tacrolimus as primary immuno-
suppression had cutaneous or osteoarticular lesions; 17% had
meningitis (8). Small sample size and lack of comparison with
patients on other immunosuppressive regimens, however,
precluded meaningful interpretation of these data.
Given the limited number of transplant recipients with
C. neoformans infection at individual institutions, accumu-
lating a sufficiently large sample was difficult, so we turned to
reports and analyses of cases for valuable data. This review
summarizes unique epidemiologic and clinical characteristics
of C. neoformans in transplant recipients, as well as variables
influencing the outcome of cryptococcal infections after
transplantation.
Methods
Cases of C. neoformans infection in transplant recipients
were identified with a MEDLINE search through 1998 by
cross-referencing the keywords “Cryptococcus neoformans”
and “transplantation” or “transplant.” Reference lists of
original articles and textbooks were reviewed for additional
cases. A patient was considered infected if C. neoformans was
cultured from a clinical specimen in the presence of signs or
symptoms of cryptococcus infection. The onset of infection
after transplantation was determined on the basis of detailed
case studies; summarized data providing only a mean or
range for the group of transplant recipients were excluded.
Cryptococcal infection was considered early-onset if it
occurred within 12 months and late-onset if it occurred >12
months after transplantation. Predictors or risk factors for
death were assessed only in detailed cases for which the
variables to be analyzed were explicitly stated.
Statistical Analysis
Patient demographic data were entered into the database
PROPHET Statistics Version 5.0 (BBN Systems and
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Technologies, Cambridge, MA). The  χ 3 or the Fisher exact test
was used to compare categorical variables. Continuous
variables (e.g., time of onset) were compared by using the
Student  t test or the Mann-Whitney U test. Multiple
comparisons were done by analysis of variance and the
Kruskal-Wallis test. A multiple regression model was used to
examine the risk factors for death.
Results
A total of 178 cases of C. neoformans infection in organ
transplant recipients were identified (1,6-9,13-56). Of these,
96 cases were individually detailed, and 82 were summarized
in reports containing 2 to 22 cases. Of 178 cases, 145, 20, and
10 were in renal, liver, and heart transplant recipients,
respectively. Three cases were reported in lung transplant
recipients, and none were described in bowel or pancreas
transplant recipients. Patients were 12 to 67 years of age
(median 44 years); 78% were male. The mean incidence of
C. neoformans infection was 2.8 per 100 transplants (0.3 to 5.3
per 100). The overall incidence was 2.4% in liver, 2.0% in lung,
3.0% in heart, and 2.8% in renal transplant recipients.
Of 127 transplant recipients who could be evaluated, 100
(79%) had azathioprine as the primary immunosuppressive
agent, 9 (7%) had tacrolimus, 11 (9%) had cyclosporine, and 7
(6%) had cyclosporine and azathioprine. Of these 127
patients, 78 were also receiving prednisone in various
dosages, 5 were not receiving prednisone, and data on
prednisone use were unavailable for 44 patients. The
incidence of cryptococcosis was 4.5 per 100 transplants in
patients who received tacrolimus, 2.4 per 100 transplants in
patients who received cyclosporine, and 3.4 per 100 transplants
in patients who received azathioprine. These rates did not differ
significantly. Rejection episodes preceding cryptococcal
infection were documented in 17 (25%) of 67 patients; rejection
had occurred a median of 7 months (from 5 days to 49 months)
before onset of infection. Eleven (18%) of 62 patients had
received augmented immunosuppression (predominantly
corticosteroids) within 6 months of onset of cryptococcosis; two
patients had received antilymphocyte preparations or OKT3
monoclonal antibodies for the treatment of allograft rejection.
Time to Onset
Cryptococcosis occurred a median of 1.6 years (from 2
days to 12 years) after transplantation. Overall, 14 (15%) of
94 cases occurred within 3 months, 10 (11%) of 94 in 3 to 6
months, 15 (16%) of 94 in 6 to 12 months, and 55 (59%) of 94
>12 months after transplantation.
The time to onset varied significantly for different types
of organ transplant recipients. The median time to onset after
transplantation was 35 months for kidney, 25 months for
heart, 8.8 months for liver, and 3 months for lung transplant
recipients (p = 0.001). Overall, cryptococcosis developed in
100% of the lung, 75% of the liver, 33% of the heart, and 30%
of the kidney transplant recipients within 12 months of
transplantation (p = 0.002) (Table 1).
C. neoformans infection tended to occur later in patients
who received azathioprine than in patients who received
tacrolimus or cyclosporine (p = 0.16). The median time to
onset was 11.4 months after transplantation in patients who
received cyclosporine, 9.2 months in patients who received
tacrolimus, and 27 months in patients who received only
azathioprine-based immunosuppression (p = 0.16). Patients
from the northeastern United States were more likely to have
early-onset cryptococcosis (i.e., infection within 12 months of
transplantation) than other patients (67% versus 31%, p =
0.004). Age, cytomegalovirus infection, or prior rejection
episodes did not correlate with early- versus late-onset
cryptococcal infection (Table 1).
Clinical Manifestations
Of 159 patients, 87 (55%) had C. neoformans infection at
the CNS site only; 20 (13%) had skin, soft tissue, or
osteoarticular infection only; and 10 (6%) had pulmonary
infection only. One patient each had prostate gland infection,
myositis, chorioretinitis, and isolated renal allograft
involvement due to C. neoformans (14,15,19,32). In 38 (24%)
of the 159 patients, more than one site of infection was
documented: CNS in 115 (72%) of 159; pulmonary in 39 (25%)
of 159; and skin, soft tissue, or osteoarticular involvement in
34 (21%) of 159 patients.
Patients receiving tacrolimus were significantly less
likely to have CNS involvement than patients receiving
nontacrolimus-based immunosuppression (78% versus 11%,
p = 0.013). Skin, soft-tissue, or osteoarticular involvement
was significantly more likely to occur with a tacrolimus- (66%)
than with a nontacrolimus-based immunosuppressive
regimen (21%, p = 0.006). When patients who received
tacrolimus were compared with those who received
cyclosporine, CNS involvement (1 [11%] of 9 versus 12 [67%]
of 18, p = 0.01) was significantly lower, and skin, soft-tissue,
or osteoarticular involvement was significantly higher with
tacrolimus than with cyclosporine immunosuppressive
therapy (6 [67%] of 9 versus 4 [22%] of 18, p = 0.04).
Table 1. Variables associated with early and late-onset Cryptococcus
neoformans infection in organ transplant recipients
Variable (no. Early onset
of patients    (within   Late onset
for whom data 12 months) (>12 months)
available)      (%)        (%) p value
Mean age in yrs 42.2 44.3 NSa
Type of transplant 0.001
  Liver (20) 75 25
  Kidney (54) 28 72
  Heart (9) 33 67
  Lung (2) 100 0
Cytomegalovirus (CMV) 50 50 NS
  infection (2)
No CMV infection (6) 67 33
Prior rejection (16) 50 50 NS
No prior rejection (45) 36 64
U.S. region 0.004b
  Northeast (24) 67 33
  West (19) 32 68
  Midwest (9) 22 78
  South (20) 40 60
Other countries
  Europe (7) 28 71
  Asia (3) 33 67
Site involved
  Lung (26) 42 58 NS
  Central nervous 40 60
     system (57)
  Skin/osteoarticular (23) 30 70
Death rate (84) 34 41
aNS = not significant, p >0.05.
bNortheastern United States versus all other regions.Synopses
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Positive blood cultures for C. neoformans were
documented in 15 (38%) of 39 transplant recipients for whom
blood cultures were performed. However, 32 (91%) of 35
patients for whom serum cryptococcal antigen was performed
had a positive serum cryptococcal antigen of 1:2 to 1:8192
(median 1:256). Leukocytosis was largely absent, the mean
peripheral leukocyte count of the patients in this review was
6,560/mm3 (range 2,000 to 12,000/mm3). Sixty-eight (74%) of
91 patients were febrile.
CNS Infection
Of 125 patients with CNS involvement
(6,7,9,13,14,16,20,22,23,26,30,31,37-39,42,43,45-47,49-
51,53,57), 122 (98%) had meningitis. Space-occupying lesions
(contrast enhancing mass lesions) due to C. neoformans were
present in three patients (7,23). Thirty-nine (62%) of 63
patients with CNS cryptococcosis had headache, 30 (48%) of
62 had confusion or lethargy, and 2 (1%) of 25 had coma on
admission. Serum cryptococcal antigen was positive in 18
(86%) of 21 patients with CNS infection (median titer 1:256;
range 1:4 to 1:4096). However, 100% of 37 patients had a
positive CSF cryptococcal antigen (median titer 1:256; range
1:4 to 1:32,768). CSF cultures yielded C. neoformans in 76
(93%) of 82 patients, and India ink preparation was positive
in 36 (77%) of 47 patients with CNS infection (Table 2).
Pulmonary Infection
Unilateral, nodular, or cavitary infiltrates were the most
frequent radiographic signs of pulmonary cryptococcosis
(1,7,9,13,23,26,29,37-40,46,49,50,54-56). Pleural effusions
were documented in 4 of 42 patients. Serum cryptococcal
antigen was detectable in 100% of 12 patients with
pulmonary lesions (titers of 1:4 to 1:8192).
Skin, Soft Tissue, or Osteoarticular Infection
Seventy-two percent of patients with cutaneous
cryptococcosis (6,9,13,16,17,21,22,25,27-29,35-37,40,44,
46,49,54-56,58) had cellulitis; C. neoformans was cultured
from an aspirate or biopsy in all these cases. Other signs
included papular or nodular lesions. Septic arthritis and
osteomyelitis were documented in five cases. Nineteen (90%)
of 21 patients with skin or osteoarticular cryptococcal
infections had positive serum cryptococcal antigen.
Death Rate
The overall death rate among organ transplant recipients
with cryptococcal infection was 72 (42%) of 172. The death
rate was 8 (40%) of 20 for liver, 57 (41%) of 139 for kidney, 6
(60%) of 10 for heart, and 1 (33%) of 3 for lung transplant
recipients. Death rates did not differ between patients on
tacrolimus and patients on other primary immunosuppres-
sive regimens (33% versus 38%, p >0.05). CNS infection
(p = 0.04), renal failure (defined as serum creatinine >1.5 mg/
dL on admission, p = 0.005), and abnormal mental status
(p = 0.03) were significant predictors of death in univariate
analysis (Table 3). In logistic regression analysis (with the
above variables in the model), only renal failure on admission
was predictive of death (odds ratio 16.4; 95% CI 1.9 to 143;
p = 0.004). The death rate was 25 (48%) of 52 in patients
receiving amphotericin B deoxycholate, 29 (38%) of 77 in
patients receiving amphotericin B plus 5 flucytosine, and 3
(21%) of 14 in patients receiving fluconazole (p = 0.16).
Fluconazole, however, was less likely to be used in patients
with CNS infection; 5% of patients with CNS compared with
23% of those with extraneural infection had received
fluconazole (p = 0.01).
Forty-nine (49%) of 101 patients with CNS cryptococcal
infection died. Of 79 patients with CNS infection who received
an antifungal agent, 22 had received amphotericin B alone, 52
had received amphotericin B plus 5-flucytosine, and 5 had
received fluconazole. Death rates did not differ between
patients with CNS infection who received amphotericin B
alone (59%) and patients with CNS infection who received
amphotericin B plus flucytosine (44%). Abnormal mental
Table 2. Cerebrospinal fluid (CSF) characteristics in organ transplant
recipients with central nervous system Cryptococcus neoformans
infection
Variable (no. of patients
whom data available)       Valuea
Opening pressure, mm H20 (17) 330   (140-700)
Leukocytes, mm3 (27)  33    (0-485)
Protein, mg/dL (27)  74    (16-715)
Glucose, mg/dL (27)  36    (4 – 113)
No. with positive India ink  80% (38/47)
No. with positive CSF cryptococcal antigen 100% (27/27)
  Titer, median (range) 1:512 (1:4-1:32,768)
No. with positive CSF culture  93%   (76/82)
No. with positive serum cryptococcal antigen  88%   (14/16)
  Titer, median (range) 1:128 (1:4-1:4096)
aMedian and range unless otherwise stated.
bNumbers of patients for whom data were available.
Table 3. Variables associated with death in organ transplant recipients
with Cryptococcus neoformans infection
Variable (no of patients Death Survival
for whom data available)   (%)     (%) p value
Mean age in yrs 43.6 43.4 NSa
Prior rejection (17) 35 65 NS
No rejection (50) 28 72
Rejection within 6 months of 33 67 NS
  onset of cryptococcosis (3)
Increased immunosuppression (11) 46 54 NS
Fever (39) 31 69 NS
No fever (21) 33 67
Renal failure (37) 43 57 0.005
No renal failure (18)   6 94
Mental status
  Abnormal (22) 54 45 0.03
  Normal (53) 28 72
Treatment NS
  AmBb (52) 48 52 (0.16)
  AmB + 5 FCc (77) 38 62
  Fluconazole (14) 21 79
Site involved 0.04d
  Central nervous system (101) 49 51
  Pulmonary (32) 22 78
  Skin/osteoarticular (28) 21 79
Type of transplant NS
  Liver (20) 40 60
  Kidney (139) 41 59
  Heart (10) 60 40
  Lung (3) 33 67
aNS = not significant, p >0.05.
bAmB = amphotericin B deoxycholate.
cFC = flucytosine.
dp value represents the difference for CNS versus other sites.Synopses
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status and absence of headache (p = 0.07) correlated with poor
outcome in patients with CNS cryptococcal infection (Table 4).
Presence of fever, CSF pleocytosis, positive blood cultures,
and CSF cryptococcal antigen titer did not correlate with
outcome (Table 4).
Discussion
C. neoformans infection was documented in 2.8% of the
organ transplant recipients, with an overall death rate of
42%. A number of findings in our study have previously not
been fully appreciated in the context of cryptococcal infections
after transplantation. For example, the type of primary
immunosuppression after organ transplantation may influ-
ence the predominant clinical manifestation. Patients
receiving tacrolimus were less likely to have CNS
involvement and more likely to have skin, soft tissue, or
osteoarticular involvement due to C. neoformans than
patients who received nontacrolimus-based immunosuppres-
sion. Furthermore, both tacrolimus and cyclosporine were
less likely to be associated with CNS involvement and more
likely to be associated with cutaneous infection than
azathioprine.
A number of biologic plausibilities exist for this
observation. Tacrolimus is a natural macrolide antifungal
product (59,60). Although its immunosuppressive effect
outweighs its antifungal action in vivo, tacrolimus is toxic to
C. neoformans in vitro by inhibition of calcineurin (59-61).
Furthermore, tacrolimus suppresses the growth of C.
neoformans at 37oC but not at 24oC, which suggests that the
target of tacrolimus, calcineurin, is required at higher body
temperatures (59,61). Thus, temperature-dependent inhibi-
tion of cryptococci by tacrolimus may prevent CNS infection
but allow growth of fungus at cooler body sites, e.g., skin, soft
tissue, and bone. Cyclosporine also possesses in vitro
antifungal activity by inhibition of calcineurin (60,61).
However, cyclosporine does not effectively penetrate the CNS,
while tacrolimus crosses the blood-brain barrier (61,62).
Thus, the relative rarity of meningitis compared with
extraneural manifestations of cryptococcosis in patients
receiving tacrolimus may merely be due to high cerebrospinal
fluid levels of tacrolimus.
Strains of C. neoformans known to be selectively
dermatotropic and rhinotropic have been demostrated in
animal models (63,64). In addition, C. neoformans serotype D
is more likely to be associated with cutaneous lesions (65).
However, the precise reason for dermatotropism or the
propensity of these strains to occur in transplant recipients
receiving calcineurin-inhibiting agents (e.g., cyclosporine and
tacrolimus) has not been elucidated.
The immunosuppressive agents (cyclosporine, tacroli-
mus, and rapamycin) have in vitro activity against fungi,
including  C. neoformans (59,61,66,67). The antifungal
activity of cyclosporine and tacrolimus is mediated by fungal
homologs of calcineurin and that of rapamycin through
complexes with TOR kinase (61,66). Mutations in calcineurin
A and B genes have been shown to confer resistance to
cyclosporine and tacrolimus and in FKBP12 gene, to tacrolimus
and rapamycin in vitro (66). In addition, TOR I mutants of
cryptococci have been identified that are resistant only to
rapamycin (66). Despite high seroprevalence of cryptococcal
antibodies in early childhood (68), cryptococcal infection is
rare in transplant recipients. These data suggest that the
immunosuppressive agents currently used may be conferring
some degree of protection against Cryptococcus. Whether
C. neoformans infections in patients receiving these immuno-
suppressive agents represent breakthrough infections due to
resistant mutants, however, remains to be determined.
Although the susceptibility of transplant recipients to
C. neoformans is well recognized, it is not known whether
cryptococcal infection in these patients is newly acquired or a
reactivation of latent infection. That cryptococcal disease may
be due to a reactivation of latent infection is suggested by the
following observations in the nontransplant setting: 1)
autopsy studies have documented pulmonary granulomas
containing C. neoformans in patients who had no history of
C. neoformans infection (69); 2) molecular typing in African
patients residing in Europe indicated that cryptococcosis
resulted from a reactivation of latent infection (70); 3)
serologic evidence of C. neoformans infection was documented
in most children in New York City in early childhood, even
though symptomatic infections were rare (68).
We previously reported that transplant recipients from
the northeastern United States were more likely to have
cryptococcosis than transplant recipients from other regions
of the United States (8). This review shows that cryptococcal
infections in patients from the Northeast developed
significantly earlier after transplantation than in other
patients. Although, there is incontrovertible evidence of
primary acquisition of cryptococcosis in isolated case reports
(71), our data suggest that C. neoformans may have a
predilection for certain geographic areas and that most
cryptococcal infections in transplant recipients may result
from a reactivation of latent infection.
Epidemiologic studies of C. neoformans have been
hampered by lack of sensitive and specific immunologic tests
to evaluate the prevalence of latent infection. New
Table 4. Variables associated with death in patients with central nervous
system Cryptococcus neoformans infection
Variable (no. of patients   Death  Survival
for whom data available)     (%)     (%) p value
Mean age in yrs 40.6 42.4 NSa
Fever (29) 34 (10/29) 66 (10/29) NS
No fever (7) 43 (3/7) 57 (4/7)
Headache (20) 25 (5/20) 75 (15/20) NS
No headache (21) 52 (11/21) 48 (10/21) (0.09)
Abnormal mental status (20) 55 (11/20) 45 (9/20) NS
Normal mental status (26) 31 (8/26) 69 (18/26)
White blood cell >20/mm3 (20) 40 (8/20) 60 (12/20) NS
White blood cell <20/mm3 (13) 62 (8/13) 38 (5/13)
Cryptococcal antigen titer 20 (2/10) 80 (8/10) NS
  >1,024 (10)
Cryptococcal antigen titer 35 (6/17) 65 (11/17)
  <1,024 (17)
Positive blood culture (8) 13 (1/8) 87 (7/8) NS
Negative blood culture (16) 50 (8/16) 50 (8/16)
Renal failure (22) 54 (12/22) 46 (10/22) 0.011
No renal failure (12)   8 (1/12) 92 (11/12)
Therapy NS
  AmBb alone (55) 47 (26/55) 53 (29/55)
  AmB + 5 FCc (32) 50 (16/32) 50 (16/32)
  Fluconazole (5) 40 (2/5) 60 (3/5)
aNS = not significant, p >0.05.
bAmB = Amphotericin B deoxycholate.
cFC = flucytosine.Synopses
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immunoblotting assays (68,72), however, have unique
implications not only for discerning whether cryptococcal
infections result from reactivation or primary acquisition but
also for identifying patients at high risk for reactivation or
patients never exposed (who may therefore be vulnerable to
primary infection).
The relative rarity of cryptococcal infections in pediatric
organ transplant recipients has been noted (55). However, the
precise reason for this is not known. If cryptococcosis
represents reactivation of latent infection in a transplant
setting and primary cryptococcal infection is acquired
asymptomatically in childhood, it is plausible that pediatric
transplant recipients may not yet have acquired the infection.
C. neoformans infection is also strikingly rare in bone marrow
transplant recipients, possibly because fluconazole prophy-
laxis is used widely for candidiasis or because thymic
regeneration in bone marrow transplant recipients may render T
cells more efficacious against cryptococci than T cells present
in solid organ transplant recipients (Heitman J, pers. comm.).
Although various clinical manifestations have been
described, molluscum contagiosum-like lesions are character-
istic of cutaneous cryptococcosis in HIV-infected patients. In
the transplant setting, cutaneous cryptococcal infection most
frequently mimicked (and was clinically indistinguishable
from) bacterial cellulitis. A unique propensity for the
extremities to be the site of cutaneous cryptococcosis in
transplant recipients was noted in this review; 94% of the
patients with cutaneous C. neoformans infections had lesions
on upper or lower extremities. Cutaneous cryptococcosis,
however, represents disseminated infection and should be
treated with systemic antifungal agents.
Elevated CSF pressure without evidence of obstructive
hydrocephalus, believed to result from basilar meningitis and
impaired reabsorption of CSF across arachnoid villi, has
recently been recognized as an important complication of
cryptococcal meningitis (73). HIV studies have shown that
high baseline opening pressure in patients with cryptococcal
meningitis correlated inversely and independently with
survival. CSF opening pressure was recorded infrequently in
organ transplant recipients. However, all 17 patients in
whom such a measurement was conducted had intracranial
pressure >140 mm of H2O; the death rate in these patients
was 8 (47%) of 17. These data underscore the need for
assessing intracranial pressure in all patients with cryptococcal
meningitis, including organ transplant recipients.
Overall, 72 (42%) of 172 of the transplant recipients with
C. neoformans infection died. Preexistent renal failure was an
independently significant predictor of death in transplant
recipients with cryptococcosis. Renal failure has been
proposed to increase the risk for cryptococcosis (62). Uremia
decreased lymphocyte transformation and chemilumines-
cence by splenic cells in C. neoformans-infected mice (74).
This review summarizes the overall impact and
highlights the key features of C.  neoformans infection in
organ transplant recipients. These include the effect of
primary immunosuppressive agents on the clinical manifes-
tations of cryptococcosis; geographic diversity in the incidence
and onset of infection posttransplantion; and variables
influencing outcome, specifically in the transplant setting.
More importantly, however, we have identified a number of
outstanding questions with implications relevant to
elucidating the pathogenesis of C. neoformans infection.
These questions involve the biologic basis of tissue tropism,
reasons for the predominance of dermatotropic strains in
recipients of tacrolimus, the role or virulence of immunosup-
pressive-agent resistant C. neoformans mutants in the
transplant setting, and the relative rarity of cryptococcal
infections in pediatric and bone marrow transplant
recipients. We caution that a retrospective study may carry
unknown bias. In this regard, our data may be considered
hypotheses generating.
Dr. Husain is an infectious diseases fellow at the University of
Pittsburgh Medical Center. His research interests include infections in
immunocompromised hosts, in particular fungal infections in organ
transplant recipients.
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